Dx & Vx Co

Dx & Vx Co FCF per Share

The Free Cash Flow per Share of Dx & Vx Co (180400.KQ) as of Nov 4, 2026 is -205.92 KRW. In the previous year, Free Cash Flow per Share was -423.82 KRW — a change of -51.41% (higher).

FCF per Share

-205.92KRW

YoY

-51.41%

Last updated:

Free Cash Flow per Share of Dx & Vx Co is 2025 -205.92 KRW. Free Cash Flow per Share of Dx & Vx Co was 2024 -423.82 KRW. It decreases by -51.41% higher compared to the previous year.

The Dx & Vx Co FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
-1,023.56 KRW
Jan 1, 2019
-366.76 KRW
Jan 1, 2020
-319.44 KRW
Jan 1, 2021
-133.74 KRW
Jan 1, 2022
-30.43 KRW
Jan 1, 2023
-471.43 KRW
Jan 1, 2024
-423.82 KRW
Jan 1, 2025
-205.92 KRW
The Dx & Vx Co FCF per Share history
YEARFCF per ShareYoY
-205.92KRW-51.41%
-423.82KRW-10.10%
-471.43KRW+1,449.40%
-30.43KRW-77.25%
-133.74KRW-58.13%
-319.44KRW-12.90%
-366.76KRW-64.17%
-1,023.56KRW+123.04%
-458.92KRW+105.89%
-222.89KRW+83.92%
-121.19KRW-330.91%
52.48KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dx & Vx Co Stock analysis

What does Dx & Vx Co do? Dx & Vx Co., Ltd. generates revenue through the Molecular Diagnosis Business segment, which focuses on manufacturing and selling DNA chips, PCR chips, and related diagnostic reagents for molecular diagnosis. The company also produces enzymes and experimental reagents for biological research, targeting laboratories and healthcare facilities that require molecular diagnostic tools. Its products are sold to institutions involved in medical testing and research, leveraging the demand for advanced diagnostic solutions in healthcare. The company's revenue streams are derived from direct sales of these specialized products to the healthcare and research sectors. Dx & Vx Co., Ltd. operates within the molecular diagnostics market, offering DNA chips, PCR chips, and diagnostic reagents as core products. The company's focus on manufacturing and selling these items positions it as a provider of essential tools for molecular biology applications. Sales are directed toward laboratories and healthcare providers seeking to enhance their diagnostic capabilities through cutting-edge technology. The business model relies on consistent demand for molecular diagnostic equipment and reagents within the medical and research industries. Dx & Vx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dx & Vx Co stock

Free Cash Flow per Share of Dx & Vx Co is -205.92 KRW in 2025.

Free Cash Flow per Share of Dx & Vx Co changed from -423.82 KRW to -205.92 KRW, representing a -51.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Dx & Vx Co since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Dx & Vx Co

All Key Metrics — Dx & Vx Co